246PTriple blinded prospective study assessing the impact of genomics & amp; artificial intelligence Watson for oncology (WFO) on MDT ’s decision of adjuvant systemic therapy for hormone receptor positive early breast carcinoma

ConclusionsTumor board decision can be more scientific& evidence based with the help of genomics& a learnt colleague in the form of Watson for Oncology. Even though the clinical experience is the important determinant of adjuvant therapy, genomic test with artificial intelligence, which includes the scientific evidence, will guide in decision making. Long term follow up is needed for the validation in our clinical setting.Legal entity responsible for the studyManipal Hospital Ethical Committee.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research